Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
The book brings together the current knowledge and future perspectives of the complex physiology and pathophysiology of gut-liver interactions in health and disease. It provides readers with a unique overview and access to knowledge that cannot be obtained elsewhere. The structure is logical and covers all aspect including the normal physiology, changes in various liver diseases, technology, sample collection and various interventions. Thus suitable for general reading, lookup for specific questions or as a reference book within the area. The book allows the reader to access all the…mehr
The book brings together the current knowledge and future perspectives of the complex physiology and pathophysiology of gut-liver interactions in health and disease. It provides readers with a unique overview and access to knowledge that cannot be obtained elsewhere.
The structure is logical and covers all aspect including the normal physiology, changes in various liver diseases, technology, sample collection and various interventions. Thus suitable for general reading, lookup for specific questions or as a reference book within the area.
The book allows the reader to access all the knowledge that has been generated within the last 10 years in this field.
Aleksander Krag is a clinical specialist in gastrointestinal and liver diseases where he is Professor and Head of Hepatology at University of Southern Denmark and Odense University Hospital. He is also Director for Centre for Liver Research. Professor Krag is educated from University of Copenhagen, where he also obtained his PhD degree. In addition he has studied leadership and innovation at Harvard Business School. Professor Krag is involved in several international research consortia in the field, including being Coordinator in Galaxy, a Horizon 2020 funded project on gut-liver interactions in liver diseases. He has been invited speaker for scientific meetings in more than 20 different countries and published more than 130 papers on clinical aspects of chronic liver disease. He has for long served in the Scientific Committee of the Baveno Group and the Executive Committee of the International Club of Ascites, to promote research in the fieldand develop international guidelines.
Inhaltsangabe
Section 1: Clinical aspects of fatty liver disease.- 1 Aspects of alcoholic fatty liver disease .- 2 Impact of obesity of adults in fatty liver disease.- 3 Impact of childhood obesity in fatty liver disease.- 4 Fetal programming in fatty liver disease.- 5 Health economics and fatty liver disease .- Section 2 : The gut liver axis in health and disease.- 6 The role of the bacterial microbiota in the gut-liver axis.- 7 The role of the virome in the gut-liver axis.- 8 The role of the fungome in the gut-liver axis.- 9 The use of metabolomics in the gut-liver axis.- 10 The use of proteomics in the gut-liver axis.- 11 Human genetics affecting liver disease.- 12 The role of microRNA in the gut-liver axis.- 13 Animal models when examining the gut-liver axis.- 14 Biomarkers of the gut-liver axis for screening, diagnosis, prognosis and prevention of disease.
Section 1: Clinical aspects of fatty liver disease.- 1 Aspects of alcoholic fatty liver disease .- 2 Impact of obesity of adults in fatty liver disease.- 3 Impact of childhood obesity in fatty liver disease.- 4 Fetal programming in fatty liver disease.- 5 Health economics and fatty liver disease .- Section 2 : The gut liver axis in health and disease.- 6 The role of the bacterial microbiota in the gut-liver axis.- 7 The role of the virome in the gut-liver axis.- 8 The role of the fungome in the gut-liver axis.- 9 The use of metabolomics in the gut-liver axis.- 10 The use of proteomics in the gut-liver axis.- 11 Human genetics affecting liver disease.- 12 The role of microRNA in the gut-liver axis.- 13 Animal models when examining the gut-liver axis.- 14 Biomarkers of the gut-liver axis for screening, diagnosis, prognosis and prevention of disease.
Section 1: Clinical aspects of fatty liver disease.- 1 Aspects of alcoholic fatty liver disease .- 2 Impact of obesity of adults in fatty liver disease.- 3 Impact of childhood obesity in fatty liver disease.- 4 Fetal programming in fatty liver disease.- 5 Health economics and fatty liver disease .- Section 2 : The gut liver axis in health and disease.- 6 The role of the bacterial microbiota in the gut-liver axis.- 7 The role of the virome in the gut-liver axis.- 8 The role of the fungome in the gut-liver axis.- 9 The use of metabolomics in the gut-liver axis.- 10 The use of proteomics in the gut-liver axis.- 11 Human genetics affecting liver disease.- 12 The role of microRNA in the gut-liver axis.- 13 Animal models when examining the gut-liver axis.- 14 Biomarkers of the gut-liver axis for screening, diagnosis, prognosis and prevention of disease.
Section 1: Clinical aspects of fatty liver disease.- 1 Aspects of alcoholic fatty liver disease .- 2 Impact of obesity of adults in fatty liver disease.- 3 Impact of childhood obesity in fatty liver disease.- 4 Fetal programming in fatty liver disease.- 5 Health economics and fatty liver disease .- Section 2 : The gut liver axis in health and disease.- 6 The role of the bacterial microbiota in the gut-liver axis.- 7 The role of the virome in the gut-liver axis.- 8 The role of the fungome in the gut-liver axis.- 9 The use of metabolomics in the gut-liver axis.- 10 The use of proteomics in the gut-liver axis.- 11 Human genetics affecting liver disease.- 12 The role of microRNA in the gut-liver axis.- 13 Animal models when examining the gut-liver axis.- 14 Biomarkers of the gut-liver axis for screening, diagnosis, prognosis and prevention of disease.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497